I think NP said 60+ people have been treated under

I think NP said 60+ people have been treated under EIND. I'm assuming Dr. P has results from those individuals and if not, he at least has anecdotal evidence of how they're faring post leronlimab.

Statistically, the 'anecdotal' results should be similar to the 50 patients already treated under the study. If results for the EIND patients are as promising as we've all been led to believe and the MOA of COVID-19 as a rantes disease is as understood and predictable as Dr. P's paper has laid out, then there should be little hesitation in stopping the trial now.

There's always a chance for anomalies, but what are the chances that the anomalies are so great that 20 additional data points will correct it to more favorable results? And if the 20 additional data points are required to skew the results back to favorable, will these results be significant (as we all believe)? If not significant, then our near term prospects for the SP are toast anyway.

Logic tells me its better to stop the study now and get on with treating as many people as possible.